Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study

Hira Mian, Naresh Bumma, Joshua Richter, Mina Awad, Timothy J. Inocencio, C. Akunna Otele, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes · 2026

Read Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study by Hira Mian, Naresh Bumma, Joshua Richter, Mina Awad, Timothy J. Inocencio, C. Akunna Otele, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13633265.txt.

Description

Hira Mian and nine colleagues published this 2026 analysis of a myeloma drug in frail patients. Multiple myeloma is a blood cancer of older adults, and frailty predicts rougher treatment courses. Data on frail patients receiving newer immune-engaging antibodies are scarce. The drug here, linvoseltamab, links immune T cells to myeloma cells. The team re-examined a trial of one hundred seventeen relapsed or resistant patients, sorting them by three frailty measures.

Frail patients made up roughly a fifth to a quarter of the group, depending on which measure was used. Response rates in frail patients sat close to those in non-frail patients under every measure. Severe side effect rates also matched closely between the groups. The authors read this as a favorable balance of benefit and risk for frail patients. They call for more study of the drug in frail groups, in trials and everyday practice.

Catalog record

CREATORHira Mian, Naresh Bumma, Joshua Richter, Mina Awad, Timothy J. Inocencio, C. Akunna Otele, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54465
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13633265

Browse the full library · About the Tower of Babel